Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). - Wikidata - wikimedia - TriplyDB

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

http://www.wikidata.org/entity/Q44357138

about

Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Metabolic Events Natriuretic Peptides and Cardiometabolic Health Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure Effects of aspirin and clopidogrel on plasma brain natriuretic peptide in patients with heart failure receiving ACE inhibitors B-type natriuretic Peptide in the critically ill with acute kidney injury.Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia.Antidepressants, autonomic function and mortality in patients with coronary heart disease: data from the Heart and Soul Study.The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial.Natriuretic Peptide testing in primary care PROCLAIM: pilot study to examine the effects of clopidogrel on inflammatory markers in patients with metabolic syndrome receiving low-dose aspirin.The Use of N-Terminal-Pro-BNP in Preterm Infants Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model.Depression and Associated Factors in Patients with Implantable Cardioverter-Defibrillators.Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma Dynamic cardiovascular risk assessment in elderly people. The role of repeated N-terminal pro-B-type natriuretic peptide testing.Surgical ventricular restoration to reverse left ventricular remodeling.How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review High sensitive troponin T and heart fatty acid binding protein: novel biomarker in heart failure with normal ejection fraction? A cross-sectional study.In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study.Biomarker predictors of cardiac hospitalization in chronic heart failure: a recurrent event analysis Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure Tachybradycardia in the isolated canine right atrium induced by chronic sympathetic stimulation and pacemaker current inhibition.Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.The biological variation of N-terminal pro-brain natriuretic peptide in postmenopausal women with type 2 diabetes: a case control study.Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).Prognostic value of estimating functional capacity with the use of the duke activity status index in stable patients with chronic heart failure Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy.Natriuretic peptides in the diagnosis and management of heart failure Linkages between anxiety and outcomes in heart failure.Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.The evolving role of nesiritide in advanced or decompensated heart failure.Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.Angiotensin II, but not aldosterone and renin, correlates positively with increased concentrations of N-terminal pro-brain natriuretic peptide in patients with chronic heart failure Elimination of vitamin D receptor in vascular endothelial cells alters vascular function Valsartan for the treatment of heart failure.NT-proBNP in heart failure: therapy decisions and monitoring.Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.B-type natriuretic peptide: practical diagnostic use for evaluating ventricular dysfunction.

P2860

Q24650348-935C5CBD-1EDD-41C1-A522-129CB9536425 Q26770151-EDA85564-4E22-4464-BF46-D3B1AACC3BE4 Q26778333-62C67F22-AED4-4E3B-BFD6-5166B6D0F302 Q26827702-05CEF454-F781-482A-861F-99FE9B4C8F74 Q27027081-96C0F529-EBCF-41E4-825B-3EDB412CF89F Q28200166-8E5BD06A-7389-41DD-8D8C-1F9B09A88A10 Q30431396-56EA2AE5-924F-43ED-B6F5-8A5F5B8D3E45 Q30475916-3EC3FE4A-52F4-4910-9783-534FFE4A1E42 Q30838926-9C5E04A1-40EA-4273-B276-C09798AFFF0E Q33526184-81556C33-F744-423D-A5AE-3B0D5B2EE831 Q33572286-C2823E95-87DE-4E1A-A46C-4EDED48DDEA9 Q33572702-25914C04-9088-4CBC-8354-E1E3228A68EA Q33580726-3A58A70A-779B-43E8-93EE-AC0B1E1C98EB Q33606538-BABD7111-8F55-4C62-8813-F3FD1AB6D8B0 Q33656655-B4D96EF5-DAB9-4271-BCA0-E2B378745A8D Q33692402-3467433A-E132-408A-A77E-BC2ED7716675 Q33733517-6A339323-3630-4279-80C4-8A41E54B6250 Q33754169-B52BB1BB-5907-43C5-9A78-5C89899D1A6D Q33932889-E3529A03-A83B-4641-A9D3-8C16EBEE33C7 Q33951088-36DB9FBE-6548-4D30-B7AF-2E6D4F027EE7 Q34027034-86E94EA0-88F1-43DF-8B24-DC73813B5EE9 Q34080388-5FDADCA1-F988-4460-9756-207C839B85BE Q34102097-2C4B7CA9-BD64-4CD0-8000-71B01085602D Q34150582-ABF76593-B0F4-4C2E-AB75-047F2E590599 Q34324771-C04DE9E6-D6BB-41CC-9AE3-C06EFB69E5DA Q34477250-F3066B02-E31F-491C-8AC4-A986F6EE513D Q34734676-E67992FC-67EA-4DBF-BF99-6CC1F2DBCD22 Q34771608-315A3062-9344-42E5-A1B3-5C8876E15BBA Q34773031-9D02BC0C-3CE4-416A-88FB-7AF3D9909707 Q35015563-F219BE76-F105-4D3E-AD35-2937E68A40BD Q35146093-37B52691-3D04-44C8-B46C-42F6F3794B1F Q35164124-21B1BADD-6B06-4289-B124-8D49DA997A12 Q35574016-B114AD1F-3D4A-455A-88A7-D2EB662AFE12 Q35580126-41B78DB7-56F4-4EA6-BDC9-A9EF8579ADF6 Q35584660-C9E50DB5-F8E3-4848-8127-55BA649F8C1F Q35601964-505FCCFF-0266-456E-AAB0-532BB1869294 Q35609704-94210F33-8631-4D1F-815C-60F4976E9D89 Q35677310-42687099-AE32-42A6-A1BA-A2CCB5FB5189 Q35748736-4B8E9A96-061B-4D5F-ABFF-A062DA1405A2 Q35796786-BF3B46A0-3419-48B6-939F-BF06A1E78DC1

P2860

Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).

http://www.wikidata.org/entity/Q44357138

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Changes in brain natriuretic p ...... eart Failure Trial (Val-HeFT).

@en

Changes in brain natriuretic p ...... Valsartan Heart Failure Trial

@nl

type

label

Changes in brain natriuretic p ...... eart Failure Trial (Val-HeFT).

@en

Changes in brain natriuretic p ...... Valsartan Heart Failure Trial

@nl

prefLabel

Changes in brain natriuretic p ...... eart Failure Trial (Val-HeFT).

@en

Changes in brain natriuretic p ...... Valsartan Heart Failure Trial

@nl

P1433

Q44357138-DD643AAB-1C97-4C22-81ED-DCD9E17B1AF2

P1476

Q44357138-04E8934C-0DB2-4F75-8A6C-97F8485B7B09

P2093

Q44357138-109ED548-A12E-4ABE-A266-05D673DD4E59

Q44357138-278BFEC5-8AB6-4701-B545-F956FF92ECBD

Q44357138-964A3147-FE84-4E88-883D-703C45C83E23

Q44357138-A50F5080-5D48-4229-AA90-16DA7AC1B3FB

Q44357138-BBA60FA0-B110-4671-8C20-54C4B778E434

Q44357138-BE6012D7-056A-4B33-A364-3AC3C5B7EA2B

Q44357138-D50A4898-534C-4A13-87F1-67AA69EAA611

Q44357138-D78CEB8A-7C16-4D9C-B158-0194693104E7

Q44357138-DE2F2063-200F-4DEC-8A69-B0B27A7A7B01

Q44357138-E04CD2E0-0B8C-4180-A7AB-A1BC9257D200

P304

Q44357138-9D6D01CA-59E5-48C6-B0E1-FDFD25C3C87B

P31

Q44357138-B4CAE159-EFE5-4FB8-A107-2BFBEEC9F15A

P356

Q44357138-A950AA45-133E-49F2-B263-2B7F5D6CBF71

P407

Q44357138-F0412C23-20A3-4B7E-871B-0C39434AB85F

P433

Q44357138-E6F90CBE-01D2-461D-A2F6-F7D4542C2325

P478

Q44357138-B10788DE-B3FE-40E6-A306-4CDA6A01EA08

P577

Q44357138-60C35BBB-ACDB-454F-9A2A-A792263FA87F

P698

Q44357138-C495C7C4-108C-4D0D-ACDF-B87DA90B4331

P921

Q44357138-75D26414-403E-4A5C-867B-303C506B8E55

Q44357138-EE437D40-3721-468D-95F6-DE5288302A5C

Q44357138-edb80385-5711-45a9-932b-125f312b41a7

P356

01.CIR.0000054164.99881.00

P1433

P1476

Changes in brain natriuretic p ...... eart Failure Trial (Val-HeFT).

@en

P2093

Aldo P Maggioni

http://www.w3.org/2001/XMLSchema#string

Gianni Tognoni

http://www.w3.org/2001/XMLSchema#string

Inder S Anand

http://www.w3.org/2001/XMLSchema#string

Jay N Cohn

http://www.w3.org/2001/XMLSchema#string

Lloyd D Fisher

http://www.w3.org/2001/XMLSchema#string

Robert D Glazer

http://www.w3.org/2001/XMLSchema#string

Roberto Latini

http://www.w3.org/2001/XMLSchema#string

Serge Masson

http://www.w3.org/2001/XMLSchema#string

Val-HeFT Investigators

http://www.w3.org/2001/XMLSchema#string

Yann-Tong Chiang

http://www.w3.org/2001/XMLSchema#string

P304

1278-1283

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000054164.99881.00

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12628948

http://www.w3.org/2001/XMLSchema#string

P921

brain natriuretic peptide